Centessa Pharmaceuticals plc Board of Directors

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Ms. Tia L. Bush

Ms. Tia L. Bush

Chief Technology & Quality Officer

Ms. Kristen K. Sheppard Esq., J.D.

Ms. Kristen K. Sheppard Esq., J.D.

Senior Vice President of Investor Relations & Corporate Communications

Mr. John J. Crowley CPA

Mr. John J. Crowley CPA

CFO and Principal Financial & Accounting Officer

Ms. Karen M. Anderson

Ms. Karen M. Anderson

Chief People Officer

Mr. Iqbal J. Hussain L.L.B.

Mr. Iqbal J. Hussain L.L.B.

General Counsel, Chief Compliance Officer & Corporate Secretary

Dr. Mario Alberto Accardi Ph.D.

Dr. Mario Alberto Accardi Ph.D.

President of the Orexin Program

Dr. Ellie Im M.D.

Dr. Ellie Im M.D.

Senior Vice President of Clinical Development & Oncology

Dr. David M. Chao Ph.D.

Dr. David M. Chao Ph.D.

Chief Administrative Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.